- Brolucizumab Shows Continued Efficacy at Year 2
- Faricimab 16-Week Efficacy at 1 Year Confirmed
- Ocular Melanoma Therapy Promising at 1 Year
- Positive 1-Year Results for Eylea in Nonproliferative Diabetic Retinopathy
- Suprachoroidal Therapy Fails in Retinal Vein Occlusion Study
- Xipere Resolves Haze in Uveitic Macular Edema
Featured Articles in the Current Issue
The next ’omic.
Developments will alter the treatment paradigm of retinal conditions.
Treatment goes beyond surgery.
- Home Monitoring Applications for Retinal Disease
- Multiple-Sclerosis–Associated Uveitis
- Treatment of Pigment Epithelial Detachments in Age-Related Macular Degeneration
- UPFRONT: Determining How to Extend Anti-VEGF Dosing
- SUBSPECIALTY NEWS: Sustained-release anti-VEGF, prophylactic ranibizumab, and more.
- FUTURE FILE: Highlighting innovative early-stage and preclinical concepts in retina
- RETINA CONVERSATIONS: Leading Adverum at the Frontier of Gene Therapy
- CODING Q&A: Coding for Optical Coherence Tomography Angiography
- NEW PRODUCT APPLICATIONS: Mobile App Enables Patients to Self-Monitor Vision Changes
- CLINICAL TRIAL UPDATE